Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0V0BO
|
||||
| Former ID |
DCL001144
|
||||
| Drug Name |
Anti-FGFR3
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Multiple myeloma [ICD9: 203; ICD10:C90] | Phase 1 | [1] | ||
| Company |
Genentech
|
||||
| Target and Pathway | |||||
| Target(s) | FGF-3 receptor | Target Info | [1] | ||
| KEGG Pathway | MAPK signaling pathway | ||||
| Ras signaling pathway | |||||
| Rap1 signaling pathway | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Signaling pathways regulating pluripotency of stem cells | |||||
| Regulation of actin cytoskeleton | |||||
| Pathways in cancer | |||||
| MicroRNAs in cancer | |||||
| Bladder cancer | |||||
| Central carbon metabolism in cancer | |||||
| PANTHER Pathway | FGF signaling pathway | ||||
| Reactome | FGFR3 mutant receptor activation | ||||
| WikiPathways | Regulation of Actin Cytoskeleton | ||||
| Endochondral Ossification | |||||
| Bladder Cancer | |||||
| Neural Crest Differentiation | |||||
| Signaling by FGFR | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of Genentech (2011). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.